![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/StefanRauh-scaled-e1600351654945-1024x1024.jpg)
WCLC 2019
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/02/C1_MCR-WCLC-2019_cover-1-225x300.png)
Read the full Report (pdf)
World Conference on Lung Cancer
07–10 September 2019 Barcelona, Spain
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/StefanRauh-scaled-e1600351654945-1024x1024.jpg)
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
CONTENTS
Online First
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression
pTMB is a feasible predictive biomarker for chemoimmunotherapy
Promising phase 1 results of novel KRAS-inhibitor in NSCLC
Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer
CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days
Other Thoracic Malignancies
Durvalumab added to etoposide improves outcomes in ES-SCLC
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/11/Figure._Percentage_of_change_from_baseline.png)
Talazoparib + low-dose temozolomide seems promising in ES-SCLC
New targets in thymic epithelial tumours may aid in identifying treatment options
Novel targets in mesothelioma may aid in developing treatment strategies
Immuno-Oncology
BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors
Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities
Targeted Therapy
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/11/Table._Cox_proportional_hazard_regression_analysis.png)
Older age and low neutrophilia inflammation predictor for osimertinib efficacy
EGFR TKI retreatment effective after earlier discontinuation
Phase 3 Trial Updates
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/11/Figure._Treatment_exposure_and_AEs_in_the_overall_population.png)
First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/11/Figure._Final_overall_survival_outcomes_in_intention-to-treat_population__Arm_B_vs_Arm_C_.png)